
CVSA Stock Forecast & Price Target
CVSA Analyst Ratings
Bulls say
Covista is projected to have continued success in the healthcare education sector due to its personalized and tech-enabled approach, supported by a growing community of alumni. The company's enrollment growth, strong revenue numbers, and potential for increased margins make it an attractive investment opportunity. With its long-term targets and expansion plans, analysts anticipate Covista's stock to rebound, making it a recommended Buy for investors.
Bears say
Covista is facing several challenges that could impact its stock performance in the near future, including potential regulatory challenges, missed long-term targets, potential liabilities from DeVry, and potential investor rotation away from the healthcare sector. Additionally, Covista's reliance on traditional on-ground coursework may serve as a barrier to competing against rapidly growing non-profit players in the online education space. Furthermore, while Covista's acquisition of Walden University and planned expansion of Chamberlain University may drive margin expansion, it remains to be seen if it can counteract potential enrollment declines and sustain long-term growth.
This aggregate rating is based on analysts' research of Adtalem Global Education Inc and is not a guaranteed prediction by Public.com or investment advice.
CVSA Analyst Forecast & Price Prediction
Start investing in CVSA
Order type
Buy in
Order amount
Est. shares
0 shares